Kogenate Bayer

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Octocog alfa

Available from:

Bayer AG 

ATC code:

B02BD02

INN (International Name):

octocog alfa

Therapeutic group:

Antihemorrhagics

Therapeutic area:

Hemofilija A

Therapeutic indications:

Liječenje i profilaksu krvarenja u bolesnika s hemofilijom A (nedostatak prirođenih faktora VIII). Ovaj lijek ne sadrži faktor Виллебранда i stoga nije navedeno u bolest pozadina Виллебранда .

Product summary:

Revision: 30

Authorization status:

povučen

Authorization date:

2000-08-04

Patient Information leaflet

                                37
B. UPUTA O LIJEKU
38
UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA
KOGENATE BAYER 250 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
KOGENATE BAYER 500 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
KOGENATE BAYER 1000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
KOGENATE BAYER 2000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
KOGENATE BAYER 3000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
rekombinantni koagulacijski faktor VIII (oktokog alfa)
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je KOGENATE Bayer i za što se koristi
2.
Što morate znati prije nego što počnete primjenjivati KOGENATE
Bayer
3.
Kako primjenjivati KOGENATE Bayer
4.
Moguće nuspojave
5.
Kako čuvati KOGENATE Bayer
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE KOGENATE BAYER I ZA ŠTO SE KORISTI
KOGENATE Bayer kao djelatnu tvar sadrži ljudski rekombinantni
koagulacijski faktor VIII (oktokog
alfa).
KOGENATE Bayer koristi se za liječenje i prevenciju krvarenja u
odraslih, adolescenata i djece bilo
koje dobi s hemofilijom A (nasljedni nedostatak faktora VIII).
Lijek ne sadrži von Willebrandov faktor te se stoga ne koristi za von
Willebrandovu bolest.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI KOGENATE BAYER
NEMOJTE PRIMJENJIVATI KOGENATE BAYER
•
ako ste alergični na oktokog alfa ili neki drugi sastojak ovog lijeka
(_naveden u dijelu 6 i na _
_kraju dijela 2_)
•
ako ste alergični na bjelančevine miša ili hrčka.
Ako niste sigurni u navedeno, posavjetujte se s Vaši
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
KOGENATE Bayer 250 IU prašak i otapalo za otopinu za injekciju
KOGENATE Bayer 500 IU prašak i otapalo za otopinu za injekciju
KOGENATE Bayer 1000 IU prašak i otapalo za otopinu za injekciju
KOGENATE Bayer 2000 IU prašak i otapalo za otopinu za injekciju
KOGENATE Bayer 3000 IU prašak i otapalo za otopinu za injekciju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka bočica sadrži nominalnu količinu od 250/500/1000/2000/3000 IU
ljudskog koagulacijskog
faktora VIII (INN: oktokog alfa).
Ljudski koagulacijski faktor VIII proizvodi se tehnologijom
rekombinantne DNK (rDNK) u
bubrežnim stanicama mladunčadi hrčka koje sadrže gen ljudskog
faktora VIII.
•
Jedan ml KOGENATE Bayer 250 IU nakon pripreme za primjenu sadrži
približno 100 IU
(250 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog
alfa).
•
Jedan ml KOGENATE Bayer 500 IU nakon pripreme za primjenu sadrži
približno 200 IU
(500 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog
alfa).
•
Jedan ml KOGENATE Bayer 1000 IU nakon pripreme za primjenu sadrži
približno 400 IU
(1000 IU / 2,5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog
alfa).
•
Jedan ml KOGENATE Bayer 2000 IU nakon pripreme za primjenu sadrži
približno 400 IU
(200 IU / 5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog
alfa).
•
Jedan ml KOGENATE Bayer 3000 IU nakon pripreme za primjenu sadrži
približno 600 IU
(3000 IU / 5 ml) ljudskog koagulacijskog faktora VIII (INN: oktokog
alfa).
Potentnost (IU) se određuje pomoću jednofaznih testova zgrušavanja
prema Mega standardu Američke
uprave za hranu i lijekove (FDA), kalibriranom prema standardu
Svjetske zdravstvene organizacije u
međunarodnim jedinicama (IU).
Specifična je aktivnost lijeka KOGENATE Bayer približno 4000 IU/mg
proteina.
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Prašak i otapalo za otopinu za injekciju (Bio-Set sustav).
Prašak: suhi bijeli do žućkasti prašak ili kolačić.
Otap
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-05-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-05-2018
Public Assessment Report Public Assessment Report Bulgarian 04-05-2018
Patient Information leaflet Patient Information leaflet Spanish 04-05-2018
Public Assessment Report Public Assessment Report Spanish 04-05-2018
Patient Information leaflet Patient Information leaflet Czech 04-05-2018
Public Assessment Report Public Assessment Report Czech 04-05-2018
Patient Information leaflet Patient Information leaflet Danish 04-05-2018
Public Assessment Report Public Assessment Report Danish 04-05-2018
Patient Information leaflet Patient Information leaflet German 04-05-2018
Public Assessment Report Public Assessment Report German 04-05-2018
Patient Information leaflet Patient Information leaflet Estonian 04-05-2018
Public Assessment Report Public Assessment Report Estonian 04-05-2018
Patient Information leaflet Patient Information leaflet Greek 04-05-2018
Public Assessment Report Public Assessment Report Greek 04-05-2018
Patient Information leaflet Patient Information leaflet English 04-05-2018
Public Assessment Report Public Assessment Report English 04-05-2018
Patient Information leaflet Patient Information leaflet French 04-05-2018
Public Assessment Report Public Assessment Report French 04-05-2018
Patient Information leaflet Patient Information leaflet Italian 04-05-2018
Public Assessment Report Public Assessment Report Italian 04-05-2018
Patient Information leaflet Patient Information leaflet Latvian 04-05-2018
Public Assessment Report Public Assessment Report Latvian 04-05-2018
Patient Information leaflet Patient Information leaflet Lithuanian 04-05-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-05-2018
Public Assessment Report Public Assessment Report Lithuanian 04-05-2018
Patient Information leaflet Patient Information leaflet Hungarian 04-05-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 04-05-2018
Public Assessment Report Public Assessment Report Hungarian 04-05-2018
Patient Information leaflet Patient Information leaflet Maltese 04-05-2018
Public Assessment Report Public Assessment Report Maltese 04-05-2018
Patient Information leaflet Patient Information leaflet Dutch 04-05-2018
Public Assessment Report Public Assessment Report Dutch 04-05-2018
Patient Information leaflet Patient Information leaflet Polish 04-05-2018
Public Assessment Report Public Assessment Report Polish 04-05-2018
Patient Information leaflet Patient Information leaflet Portuguese 04-05-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 04-05-2018
Public Assessment Report Public Assessment Report Portuguese 04-05-2018
Patient Information leaflet Patient Information leaflet Romanian 04-05-2018
Public Assessment Report Public Assessment Report Romanian 04-05-2018
Patient Information leaflet Patient Information leaflet Slovak 04-05-2018
Public Assessment Report Public Assessment Report Slovak 04-05-2018
Patient Information leaflet Patient Information leaflet Slovenian 04-05-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 04-05-2018
Public Assessment Report Public Assessment Report Slovenian 04-05-2018
Patient Information leaflet Patient Information leaflet Finnish 04-05-2018
Public Assessment Report Public Assessment Report Finnish 04-05-2018
Patient Information leaflet Patient Information leaflet Swedish 04-05-2018
Public Assessment Report Public Assessment Report Swedish 04-05-2018
Patient Information leaflet Patient Information leaflet Norwegian 04-05-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 04-05-2018
Patient Information leaflet Patient Information leaflet Icelandic 04-05-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 04-05-2018

Search alerts related to this product

View documents history